Tonometry(1) and Duplex Ultrasound(2) to Predict CV Events in to be Treated Patients With an AAA
Key facts
- Where
- Apeldoorn, Deventer, Ede, Enschede, Nijmegen, and Veldhoven, NetherlandsSee the 7 sites
Where in Netherlands
- Gelre HospitalsApeldoorn, NetherlandsContact: Hessel BuscherTaking people
- Deventer HospitalDeventer, NetherlandsContact: Lieuwe van der HemTaking people
- Ziekenhuis Gelderse ValleiEde, NetherlandsContact: Hans SybrandyTaking people
- Medisch Spectrum TwenteEnschede, NetherlandsContact: Theo MentingTaking people
- Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsContact: Bianca Bendermacher, MDTaking people
- RadboudumcNijmegen, NetherlandsContact: Dick Thijssen, ProfTaking people
- Maxima Medical CenterVeldhoven, NetherlandsContact: Maarten LoosTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Rijnstate Hospital
- Trial code
- NCT04183426
- Record updated
- 6 March 2025
- Original description
Abdominal aortic aneurysm (AAA) is a common vascular disease and associated with risk of rupture, but also with a high cardiovascular (CV) event rate. A key difficulty in AAA is predicting these life-threatening complications, which are strongly linked to vascular health. In 2013, the SMART risk score was developed to calculate the risk of the patients for recurrent vascular events based on clinical characteristics. Recently, a novel, easy to perform, non-invasive test of endothelial function (the carotid artery reactivity (CAR) test), reflecting target organ damage, has been introduced. The CAR is a simple, quick (5-min), non-invasive test that uses ultrasound to examine the carotid artery in response to sympathetic stimulation by placing one hand in cold water. This test shows strong agreement with both coronary and aortic responses to sympathetic stimulation and predicted CV-events in patients with peripheral arterial disease.Read full original descriptionShow less
Tonometry(1) and Duplex Ultrasound(2) to Predict Cardiovascular Events in to be Treated Patients With an Abdominal Aortic Aneurysm (One-Two-Treat Trial)
Abdominal aortic aneurysm (AAA) is a common vascular disease and associated with risk of rupture, but also with a high cardiovascular (CV) event rate. A key difficulty in AAA is predicting these life-threatening complications, which are strongly linked to vascular health. In 2013, the SMART risk score was developed to calculate the risk of the patients for recurrent vascular events based on clinical characteristics. Recently, a novel, easy to perform, non-invasive test of endothelial function (the carotid artery reactivity (CAR) test), reflecting target organ damage, has been introduced. The CAR is a simple, quick (5-min), non-invasive test that uses ultrasound to examine the carotid artery in response to sympathetic stimulation by placing one hand in cold water. This test shows strong agreement with both coronary and aortic responses to sympathetic stimulation and predicted CV-events in patients with peripheral arterial disease.
The aim of this prospective 2-year follow-up study is to investigate the predictive capacity of the CAR-test for development of CV-events after elective AAA repair in comparison to the SMART risk score. Secondary objectives are to investigate the predictive capacity of arterial stiffness measurements and the post-operative CAR-test for development of CV-events and to evaluate health status scores to provide insight if these scores can support clinical decision making.
Inclusion: Male or female at least 18 years old; Informed consent form understood and signed and patient agrees to follow- up visits; Has an infrarenal or juxtarenal abdominal aortic aneurysm (AAA), scheduled for elective repair (i.e open repair, EVAR, FEVAR and CHEVAR) according to standard practice.
Exclusion: Psychiatric or other condition that may interfere with the study; Presence of Raynaud's phenomenon, Marfan syndrome, chronic pain syndrome at upper extremity(s), presence of an AV fistula or shunt, open wounds to the upper extremity(s), and/or scleroderma associated with placing the hand in ice water; Recent (<3 months) presence of angina pectoris, myocardial infarction, cerebral infarction, and/or heart failure, or PAD treatment; Life expectancy < 2 years; Participating in another clinical study, interfering on outcomes; Increased risk for coronary spasms (score Rose-questionnaire ≥2.